Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) Confident in the Future of Bria-IMT Following its Demonstrated Success in Clinical Trials

share with twitter share with LinkedIn share with facebook
share via e-mail
01/11/2019 | 12:46pm EST

BriaCell Therapeutics (OTC: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, sees a promising future for its lead product candidate, Bria-IMT. An article discussing the company reads, “The company recently presented promising results for two of its clinical studies (monotherapy and combination study of Bria-IMT with pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc.]) for patients with advanced breast cancer during the 2018 San Antonio Breast Cancer Symposium in Texas (http://nnw.fm/5YriX).  … ‘I am very excited about our data continuing to show robust biological activity of Bria-IMT™ in advanced breast cancer,’ Dr. Bill Williams, BriaCell’s president & CEO, said of the company’s presentation at the international symposium that attracted over 7,000 academic and private physicians and researchers (http://nnw.fm/Po3A0).  ‘These findings also reinforce our product development strategy for Bria-OTS™, BriaCell’s novel off-the-shelf personalized immunotherapy, by showing predictability of the anti-tumor responses in patients using a relatively simple and inexpensive HLA test.’”

To view the full article, visit http://nnw.fm/Tm2FS

About BriaCell

BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com.

To receive instant SMS alerts, text STOCKS to 77948

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Copyright © 2015 - 2019 NetworkNewsWire, source NetworkNewsWire

Stocks mentioned in the article
ChangeLast1st jan.
BRIACELL THERAPEUTICS CORP 0.00% 0.085 Delayed Quote.6.25%
MERCK AND COMPANY 0.36% 75.87 Delayed Quote.-0.71%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK AND COMPANY
01/21Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian de..
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
01/18MERCK AND : Mercks keytruda cuts death risk in oesophageal cancer
01/17Phoenix, Roche partner to develop TNBC biomarker
01/17EXELIXIS : enters crowded liver cancer field with Cabometyx, taking on Bayer, BM..
01/17PFIZER : BMS gets new OK for Opdivo/Yervoy in kidney cancer
01/16Bayer to increase patient access to specialty drugs with ZappRx digital platf..
01/16MERCK AND : KEYTRUDA Reduced Risk of Death by 31 Percent
01/16EISAI : Post-Hoc Analyses from Pivotal Phase 3 REFLECT Trial of LENVIMA in Unres..
01/15MSKCC says senior execs may not hold industry board seats
More news
Financials ($)
Sales 2018 42 293 M
EBIT 2018 13 865 M
Net income 2018 7 942 M
Debt 2018 17 175 M
Yield 2018 2,60%
P/E ratio 2018 30,81
P/E ratio 2019 19,08
EV / Sales 2018 5,07x
EV / Sales 2019 4,77x
Capitalization 197 B
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 81,5 $
Spread / Average Target 7,5%
EPS Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
James H. Scholefield Chief Information & Digital Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-0.71%197 291
JOHNSON & JOHNSON1.27%350 508
PFIZER-2.57%246 674
NOVARTIS5.09%227 840
ROCHE HOLDING LTD.5.96%223 053
AMGEN4.73%129 916